Survival and biomarker analysis for ovarian mucinous carcinoma according to invasive patterns: retrospective analysis and review literature

Table 1 Characteristics of 49 patients with ovarian mucinous carcinoma according to invasive patterns

	Ovarian mucinous carcinoma with infiltrative invasion	Ovarian mucinous carcinoma with expansile invasion	p-Value
Variables	n = 25	n = 24	p-Value
Age (years)			0.16
< 51	16 (64)	10 (42)
≥ 51	9 (36)	14 (58)
FIGO stage (%)			0.26
I	16 (64)	20 (84)
II	1 (4)	1 (4)
III	6 (24)	1 (4)
IV	2 (8)	2 (8)
Tumor site (%)			0.35
Unilateral	21 (84)	23 (96)
Bilateral	4 (4)	1 (4)
Standard surgery (%)			0.78
Yes	15 (60)	13 (54)
No	10 (40)	11 (46)
Peritoneal cytology (%)			0.78
Positive	12 (48)	10 (42)
Negative	13 (52)	14 (58)
Residual tumor diameter at PDS (%)			0.58
No residual tumor	18 (72)	20 (83)
< 1.0 cm	1 (4)	1 (4)
≥ 1.0 cm	6 (24)	3 (13)
Adjuvant chemotherapy (%)			0.02
Not done	4 (16)	12 (50)
Done	21 (84)	12 (50)
Regimen of the adjuvant chemotherapy
Paclitaxel and carboplatin	5 (24)	2 (17)	0.20
Platinum-based therapy ^a	16 (76)	10 (83)
Response rate of adjuvant chemotherapy for patients with residual tumor which received adjuvant chemotherapy (%)			0.20
CR/PR	3 (43)	3 (100)
S D/PD	4 (57)	0 (0)
Recurrence (%)			< 0.01
Yes	13 (52)	2 (8)
No	12 (48)	22 (92)

Abbreviations:SD standard deviation; FIGO International Federation of Gynecology and Obstetrics; PDS primary debulking surgery; cm centimeter; CR complete response; PR partial response; SD stable disease; PD progressive disease
^a Platinum-based therapy included the combination with cyclophosphamide, doxorubicin, and cisplatin, the combination with cyclophosphamide and cisplatin, the combination with etoposide and cisplatin, and the combination with irinotecan and nedaplatin

ISSN: 1757-2215